Fitness
Fitness

AHA to Scrutinize Aggressive Blood Pressure Control Beyond SPRINT Cohorts

By Claire Ashworth ·

Optimal-Stroke and Optimal-Diabetes Results

The OPTIMAL-Stroke and OPTIMAL-Diabetes studies will debut on Saturday. These research efforts address gaps left by the SPRINT study, completed over a decade ago. Both aimed for a systolic blood pressure below 120 mmHg for cardiovascular protection. The target group ranged from 130 to 180 mmHg. OPTIMAL-Stroke focused on ischemic stroke survivors. OPTIMAL-Diabetes targeted individuals with type 2 diabetes and high risk. These groups were excluded from the 2017 SPRINT study.

STREAM Study on Statin Use

The STREAM trial will feature a crucial non-inferiority results session on Saturday afternoon. This study is broader than previous SITE/SAGA investigations. It will provide substantial data on statin risks. This applies especially to older, non-cardiovascular patients stopping statin therapy.

Early Invasive Approach for Stable Ischemic Heart Disease

The early invasive approach—stenting or bypass surgery—remains under review. Major trials like ISCHEMIA, ISCHEMIA-CKD, and COURAGE yielded neutral results. These studies offer a chance to see if clinical follow-up changes the outlook. This will be presented on Saturday morning.

Inflammation and Lp(a) Therapies

Developing drugs are also on the agenda. Researchers will clarify if reducing inflammation and lipoprotein(a) [Lp(a)] offers cardiovascular benefits. The ZEUS report on ziltivekib (an interleukin-6 inhibitor) is relevant. The Lp(a)HORIZON study, testing pelacarsen, will also be featured. Both have initial, disappointing public data.

Electrophysiology Updates

Sunday presentations highlight OptimPacing. This compares left bundle branch pacing versus right ventricular pacing for AV block. SUPERIOR also evaluates sacubitril/valsartan (Entresto). It assesses atrial fibrillation recurrence prevention post-catheter ablation in hypertensive patients.

GLP-1 Agonist in OSA and Obesity

Monday morning features the ATTAIN-OS trial result. This placebo-controlled study examines forglipron (Foundayo), a GLP-1 receptor agonist. The trial subjects have obstructive sleep apnea and obesity or overweight status.

AI-Assisted ECG for LV Systolic Function

Smartwatches with AI-assisted ECGs offer an accessible LV systolic function assessment. The WATCH-LV study will present this innovation. This will occur during the final AHA results session on Monday. These events show modern cardiology's rapid complexity. They demand focused attention from researchers and clinicians.